These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19627185)

  • 1. New concepts in herpes simplex virus vaccine development: notes from the battlefield.
    Dasgupta G; Chentoufi AA; Nesburn AB; Wechsler SL; BenMohamed L
    Expert Rev Vaccines; 2009 Aug; 8(8):1023-35. PubMed ID: 19627185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown.
    Chentoufi AA; Kritzer E; Yu DM; Nesburn AB; Benmohamed L
    Clin Dev Immunol; 2012; 2012():187585. PubMed ID: 22548113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge.
    Zhang X; Chentoufi AA; Dasgupta G; Nesburn AB; Wu M; Zhu X; Carpenter D; Wechsler SL; You S; BenMohamed L
    Mucosal Immunol; 2009 Mar; 2(2):129-143. PubMed ID: 19129756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
    Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
    J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology.
    Sandgren KJ; Truong NR; Smith JB; Bertram K; Cunningham AL
    Methods Mol Biol; 2020; 2060():31-56. PubMed ID: 31617171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.
    Samandary S; Kridane-Miledi H; Sandoval JS; Choudhury Z; Langa-Vives F; Spencer D; Chentoufi AA; Lemonnier FA; BenMohamed L
    Hum Immunol; 2014 Aug; 75(8):715-29. PubMed ID: 24798939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?
    Ghiasi H
    J Virol; 2017 Dec; 91(23):. PubMed ID: 29138327
    [No Abstract]   [Full Text] [Related]  

  • 9. A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes.
    Awasthi S; Friedman HM
    J Infect Dis; 2014 Mar; 209(6):813-5. PubMed ID: 24285847
    [No Abstract]   [Full Text] [Related]  

  • 10. The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.
    Kuo T; Wang C; Badakhshan T; Chilukuri S; BenMohamed L
    Vaccine; 2014 Nov; 32(50):6733-45. PubMed ID: 25446827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
    Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine value profile for herpes simplex virus.
    Johnston C; Scheele S; Bachmann L; Boily MC; Chaiyakunapruk N; Deal C; Delany-Moretlwe S; Lee S; Looker K; Marshall C; Mello MB; Ndowa F; Gottlieb S
    Vaccine; 2024 Jul; 42(19S1):S82-S100. PubMed ID: 39003018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inactivated herpes simplex virus types 1 and 2 divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes].
    Barinskiĭ IF; Makhmudov FR
    Vopr Virusol; 2010; 55(1):35-40. PubMed ID: 20364670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.
    Gottlieb SL; Giersing B; Boily MC; Chesson H; Looker KJ; Schiffer J; Spicknall I; Hutubessy R; Broutet N;
    Vaccine; 2019 Nov; 37(50):7336-7345. PubMed ID: 28647165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and prospects for development of an HSV vaccine.
    Johnston C; Koelle DM; Wald A
    Vaccine; 2014 Mar; 32(14):1553-60. PubMed ID: 24016811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vaccines as an approach to the immunocorrection in herpetic infections].
    Barinskiĭ IF; Alimbarova LM; Lazarenko AA; Makhmudov FR; Sergeev OV
    Vopr Virusol; 2014; 59(1):5-11. PubMed ID: 25065139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?
    Posavad CM; Wald A; Hosken N; Huang ML; Koelle DM; Ashley RL; Corey L
    J Immunol; 2003 Apr; 170(8):4380-8. PubMed ID: 12682275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107
    Khan AA; Srivastava R; Vahed H; Roy S; Walia SS; Kim GJ; Fouladi MA; Yamada T; Ly VT; Lam C; Lou A; Nguyen V; Boldbaatar U; Geertsema R; Fraser NW; BenMohamed L
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.